COVID Articles
Updated COVID-19 vaccines from Moderna, Novavax-Sanofi and Pfizer-BioNTech have been approved by the U.S. Food and Drug Administration.
ccording to three different studies, COVID-19 vaccines were associated with a lower risk of major adverse cardiovascular events (MACE), in addition to other outcomes, particularly among older adults.
A recent study in Taiwan that examined the vaccine effectiveness (VE) against moderate to severe COVID-19 infection in children aged 6 to 11 years found the Pfizer/BioNTech BNT162b2 VE was 69.9 percent and the Moderna mRNA-1273 VE was 75.5 percent during Omicron BA.2/BA.5 predominance in 2022.
Researchers have discovered why the unusual side effect of a blood clot that impacted some recipients of the Oxford/AstraZeneca and Johnson & Johnson COVID-19 vaccines occurred.
A vaccine candidate called GBP511 that builds upon a self-assembling nanoparticle technology has begun human clinical testing in Australia.
According to a study that analyzed the Veteran’s Health Administration records found there is no evidence to suggest COVID-19 vaccination increases the risk of developing idiopathic inflammatory myositis.
In a national cohort study of 28 million individuals, researchers found no increased risk of four-year all-cause mortality in individuals aged 18 to 59 years vaccinated against COVID-19, further supporting the safety of the mRNA vaccines that are widely used worldwide.
A study has found that for patients with certain types of advanced lung or skin cancer, administration of a SARS-CoV-2 mRNA vaccine within 100 days of starting immune checkpoint inhibitors is associated with increased overall survival.
A new study has found people have an increased risk of major cardiovascular events following viral infections such as SARS-CoV-2, influenza, HIV, hepatitis C and varicella zoster virus.
Since the U.S. Food and Drug Administration released its 2025-2026 formula approvals on Aug. 2, significantly restricting who can access the vaccines for the first time since their release, several states have issued their own guidance about COVID-19 vaccines.
Pfizer and BioNTech updated mRNA COVID-19 vaccine for the 2025-2026 season produced strong immune responses, boosting neutralizing antibody levels by at least fourfold in older people and those with underlying medical conditions.